OCUL – Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.OCUL
$8.47Name : Ocular Therapeutix, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,854,594,176.00
EPSttm : -1.44
Ocular Therapeutix, Inc.
$8.47
3.80%$0.31
OCUL — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
12.4
Margin Of Safety %
Put/Call OI Ratio
0.3
EPS Next Q Diff
-0.01
EPS Last/This Y
-0.2
EPS This/Next Y
0.09
Price
8.46
Target Price
26
Analyst Recom
1.09
Performance Q
-14.18
Upside
-479.2%
Beta
0.92
Ticker: OCUL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | OCUL | 9.27 | 0.21 | 0.27 | 44913 |
| 2026-05-12 | OCUL | 9.15 | 0.21 | 0.13 | 45543 |
| 2026-05-13 | OCUL | 9.24 | 0.21 | 0.85 | 46265 |
| 2026-05-14 | OCUL | 9.49 | 0.23 | 0.35 | 47536 |
| 2026-05-15 | OCUL | 9.16 | 0.23 | 0.61 | 48627 |
| 2026-05-18 | OCUL | 8.37 | 0.25 | 0.37 | 42689 |
| 2026-05-19 | OCUL | 7.99 | 0.26 | 0.31 | 44602 |
| 2026-05-20 | OCUL | 8.02 | 0.27 | 0.50 | 45883 |
| 2026-05-21 | OCUL | 8.22 | 0.27 | 0.89 | 46731 |
| 2026-05-22 | OCUL | 8.23 | 0.28 | 1.51 | 47640 |
| 2026-05-26 | OCUL | 8.31 | 0.29 | 0.23 | 46612 |
| 2026-05-27 | OCUL | 8.54 | 0.29 | 0.38 | 47127 |
| 2026-05-28 | OCUL | 9.16 | 0.29 | 0.17 | 47477 |
| 2026-05-29 | OCUL | 9.03 | 0.29 | 0.39 | 47706 |
| 2026-06-02 | OCUL | 8.31 | 0.29 | 0.28 | 47253 |
| 2026-06-03 | OCUL | 8.36 | 0.29 | 0.21 | 47846 |
| 2026-06-04 | OCUL | 8.79 | 0.29 | 0.15 | 47980 |
| 2026-06-05 | OCUL | 8.26 | 0.29 | 0.17 | 48090 |
| 2026-06-08 | OCUL | 8.15 | 0.29 | 0.53 | 47548 |
| 2026-06-09 | OCUL | 8.46 | 0.30 | 0.13 | 47780 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | OCUL | 9.27 | -4.3 | - | -1.62 |
| 2026-05-12 | OCUL | 9.15 | -4.3 | - | -1.62 |
| 2026-05-13 | OCUL | 9.24 | -4.3 | - | -1.62 |
| 2026-05-14 | OCUL | 9.50 | -4.3 | - | -1.62 |
| 2026-05-15 | OCUL | 9.16 | -4.3 | - | -1.62 |
| 2026-05-18 | OCUL | 8.38 | -4.3 | - | -1.62 |
| 2026-05-19 | OCUL | 7.99 | -4.3 | - | -1.62 |
| 2026-05-20 | OCUL | 8.01 | -4.3 | - | -1.62 |
| 2026-05-21 | OCUL | 8.21 | -4.3 | - | -1.62 |
| 2026-05-22 | OCUL | 8.24 | -4.3 | - | -1.62 |
| 2026-05-26 | OCUL | 8.30 | -4.3 | - | -1.62 |
| 2026-05-27 | OCUL | 8.54 | -4.3 | - | -1.62 |
| 2026-05-28 | OCUL | 9.15 | -4.3 | - | -1.62 |
| 2026-05-29 | OCUL | 9.02 | -4.3 | - | -1.62 |
| 2026-06-01 | OCUL | 8.93 | -4.3 | - | -1.62 |
| 2026-06-02 | OCUL | 8.31 | -4.3 | - | -1.62 |
| 2026-06-03 | OCUL | 8.36 | -4.3 | - | -1.62 |
| 2026-06-04 | OCUL | 8.79 | -4.3 | - | -1.62 |
| 2026-06-05 | OCUL | 8.26 | -4.3 | - | -1.62 |
| 2026-06-08 | OCUL | 8.17 | -4.3 | - | -1.62 |
| 2026-06-09 | OCUL | 8.46 | -4.3 | - | -1.62 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | OCUL | -0.78 | 4.11 | 12.39 |
| 2026-05-12 | OCUL | -0.78 | 4.11 | 12.52 |
| 2026-05-13 | OCUL | -0.78 | 4.11 | 12.52 |
| 2026-05-14 | OCUL | -0.78 | 4.11 | 12.52 |
| 2026-05-15 | OCUL | -0.78 | 4.11 | 12.52 |
| 2026-05-18 | OCUL | -0.78 | 3.97 | 12.52 |
| 2026-05-19 | OCUL | -0.78 | 3.97 | 12.52 |
| 2026-05-20 | OCUL | -0.78 | 3.97 | 12.52 |
| 2026-05-21 | OCUL | -0.78 | 3.97 | 12.52 |
| 2026-05-22 | OCUL | -0.78 | 3.97 | 12.52 |
| 2026-05-26 | OCUL | -0.78 | 1.29 | 12.41 |
| 2026-05-27 | OCUL | -0.71 | 1.29 | 12.41 |
| 2026-05-28 | OCUL | -0.71 | 1.29 | 12.40 |
| 2026-05-29 | OCUL | -0.86 | 1.29 | 12.40 |
| 2026-06-02 | OCUL | -0.86 | 0.62 | 12.40 |
| 2026-06-03 | OCUL | -0.86 | 0.62 | 12.40 |
| 2026-06-04 | OCUL | -0.86 | 0.62 | 12.40 |
| 2026-06-05 | OCUL | -0.93 | 0.62 | 12.40 |
| 2026-06-08 | OCUL | -0.93 | 0.51 | 12.40 |
| 2026-06-09 | OCUL | -0.93 | 0.51 | 12.40 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.4
Avg. EPS Est. Current Quarter
-0.41
Avg. EPS Est. Next Quarter
-0.41
Insider Transactions
-0.93
Institutional Transactions
0.51
Beta
0.92
Average Sales Estimate Current Quarter
13
Average Sales Estimate Next Quarter
14
Fair Value
Quality Score
44
Growth Score
38
Sentiment Score
4
Actual DrawDown %
48.5
Max Drawdown 5-Year %
-86.1
Target Price
26
P/E
Forward P/E
PEG
P/S
35.64
P/B
3.19
P/Free Cash Flow
EPS
-1.46
Average EPS Est. Cur. Y
-1.62
EPS Next Y. (Est.)
-1.53
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-558.24
Relative Volume
0.76
Return on Equity vs Sector %
-77.4
Return on Equity vs Industry %
-61.3
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.22
EBIT Estimation
◆
OCUL
Healthcare
$8.47
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
46.4
Range 1M
27%
Sup Dist
5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-12.5%
EPS NY
9.1%
52W%
20.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+207% upside
Upside
+207%
Quality
44
Ocular Therapeutix, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 325
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
OCUL
Latest News
—
Caricamento notizie per OCUL…
stock quote shares OCUL – Ocular Therapeutix, Inc. Stock Price stock today
news today OCUL – Ocular Therapeutix, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCUL – Ocular Therapeutix, Inc. yahoo finance google finance
stock history OCUL – Ocular Therapeutix, Inc. invest stock market
stock prices OCUL premarket after hours
ticker OCUL fair value insiders trading